BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17051323)

  • 1. 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Reardon DA; Coleman RE
    Mol Imaging Biol; 2006; 8(6):340-7. PubMed ID: 17051323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.
    Galldiks N; Ullrich R; Schroeter M; Fink GR; Jacobs AH; Kracht LW
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):84-92. PubMed ID: 19662410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis.
    Laymon CM; Oborski MJ; Lee VK; Davis DK; Wiener EC; Lieberman FS; Boada FE; Mountz JM
    Magn Reson Imaging; 2012 Nov; 30(9):1268-78. PubMed ID: 22819581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and
    Pala A; Reske SN; Eberhardt N; Scheuerle A; König R; Schmitz B; Beer AJ; Wirtz CR; Coburger J
    Neurosurg Rev; 2019 Jun; 42(2):471-479. PubMed ID: 29808321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
    Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
    Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.
    Holodny AI; Makeyev S; Beattie BJ; Riad S; Blasberg RG
    AJNR Am J Neuroradiol; 2010 Jun; 31(6):1042-8. PubMed ID: 20150307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI.
    Viel T; Talasila KM; Monfared P; Wang J; Jikeli JF; Waerzeggers Y; Neumaier B; Backes H; Brekka N; Thorsen F; Stieber D; Niclou SP; Winkeler A; Tavitian B; Hoehn M; Bjerkvig R; Miletic H; Jacobs AH
    J Nucl Med; 2012 Jul; 53(7):1135-45. PubMed ID: 22689925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.
    Corroyer-Dulmont A; Pérès EA; Gérault AN; Savina A; Bouquet F; Divoux D; Toutain J; Ibazizène M; MacKenzie ET; Barré L; Bernaudin M; Petit E; Valable S
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):682-94. PubMed ID: 26537287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
    Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
    Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
    Vlassenko AG; Thiessen B; Beattie BJ; Malkin MG; Blasberg RG
    J Neurooncol; 2000; 46(3):249-59. PubMed ID: 10902856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.